This story is from August 23, 2017
Johnson & Johnson fined $417 million in talc cancer suit
Johnson & Johnson (J&J) was ordered by a
The jury found the parent company and its consumer-products unit liable on Monday for failing to warn a woman over the alleged risk of the
The trial in Los Angeles was the first before a state jury outside Missouri, where the company lost four out of five trials over the past two years and got hit with verdicts as high as $110 million. J&J is appealing the verdicts and in Ju ne succeeded in halting a trial in St Louis after the US Supreme Court made it more difficult for out-of-state plaintiffs to join lawsuits in state courts that are deemed favourable to their claims.
The company will appeal, said spokeswoman Carol Goodrich. “We are guided by the science, which supports the safety of Johnson's Baby Powder,'' she said. “We are preparing for additional trials in the US and we will continue to defend the safety of Johnson's Baby Powder.“
J&J, the world's largest healthcare company , is accused of ignoring studies linking its baby powder and 'Shower to Shower' talc products to ovarian cancer and failing to warn customers about the risk.
Mark Robinson, a lawyer for plaintiff
“J&J needs to see they not only have verdicts against them in St Louis, they now also have them in Los Angeles,“ Robinson said. “There's a problem all over the country with women using talcum powder on daily basis for 10, 20, 30, 40 years.“
Echeverria started using J&J's talc powder products when she was 11. She was diagnosed with ovarian cancer in 2007. The $417-million verdict on Monday is the third-largest jury award in the US so far in 2017.
Los Angeles
jury to pay $417 million to a 62-year-old woman who blamed her ovarian cancer on the company's talc, in the first California trial over the product.baby powder
. The verdict includes $347 million in punitive damages. J&J, which faces 5,500 claims in US courts, has lost four previous jury verdicts in St Louis for a total of $300 million.The trial in Los Angeles was the first before a state jury outside Missouri, where the company lost four out of five trials over the past two years and got hit with verdicts as high as $110 million. J&J is appealing the verdicts and in Ju ne succeeded in halting a trial in St Louis after the US Supreme Court made it more difficult for out-of-state plaintiffs to join lawsuits in state courts that are deemed favourable to their claims.
The company will appeal, said spokeswoman Carol Goodrich. “We are guided by the science, which supports the safety of Johnson's Baby Powder,'' she said. “We are preparing for additional trials in the US and we will continue to defend the safety of Johnson's Baby Powder.“
J&J, the world's largest healthcare company , is accused of ignoring studies linking its baby powder and 'Shower to Shower' talc products to ovarian cancer and failing to warn customers about the risk.
Mark Robinson, a lawyer for plaintiff
Eva Echeverria
, said outside the courtroom that J&J should start warning women immediately about the risks of its talcum powder.Echeverria started using J&J's talc powder products when she was 11. She was diagnosed with ovarian cancer in 2007. The $417-million verdict on Monday is the third-largest jury award in the US so far in 2017.
Popular from Business
- US indicts Gautam Adani for bribing officials in India, misleading investors; issues arrest warrants
- Elon Musk takes witty dig at Jaguar's new logo, asks 'Do you sell cars?' - here's how Jaguar responded
- Here are US charges against Gautam Adani
- Kenya scraps airport, power deals with Adani Group
- Who is Sagar Adani, accused of bribery and fraud charges along with Gautam Adani in the US?
end of article
Trending Stories
- Will banks open only for 5 days a week? Here’s what you should know about IBA’s proposal
- India set to be third largest economy, says S&P Global
- Dalal Street bull run continues! BSE Sensex crosses 69,000 for the first time; Nifty above 20,800
- Byju’s reduces notice period for employees as troubles mount
03:08 Sensex surges over 900 points, Nifty above 20,550 as BJP state election wins bolster Modi's Lok Sabha 2024 prospects- UltraTech to buy building materials business of Kesoram in 7,600 crore deal
- Tata Technologies stock debuts at a bumper 140% premium; share price at Rs 1200 on BSE
Visual Stories
- NEET UG 2024 result awaited: Top 10 NIRF-ranked medical colleges of India
- 7 New Expected Bullet Train Routes in India
- 10 Upcoming High-Speed Expressways That Will Change Highway Travel In India
- 8 Transformational Indian Railways Projects You Shouldn’t Miss
- Why Sensex, Nifty50 Hit New Highs, M-Cap At $5 Trillion: Top Reasons
TOP TRENDS
UP NEXT
Start a Conversation
Post comment